• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体基因内缺失与前列腺癌进展模型中的雄激素受体剪接变体表达和活性相关。

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

机构信息

Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

出版信息

Oncogene. 2012 Nov 8;31(45):4759-67. doi: 10.1038/onc.2011.637. Epub 2012 Jan 23.

DOI:10.1038/onc.2011.637
PMID:22266865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3337879/
Abstract

Reactivation of the androgen receptor (AR) during androgen depletion therapy (ADT) underlies castration-resistant prostate cancer (CRPCa). Alternative splicing of the AR gene and synthesis of constitutively active COOH-terminally truncated AR variants lacking the AR ligand-binding domain has emerged as an important mechanism of ADT resistance in CRPCa. In a previous study, we demonstrated that altered AR splicing in CRPCa 22Rv1 cells was linked to a 35-kb intragenic tandem duplication of AR exon 3 and flanking sequences. In this study, we demonstrate that complex patterns of AR gene copy number imbalances occur in PCa cell lines, xenografts and clinical specimens. To investigate whether these copy number imbalances reflect AR gene rearrangements that could be linked to splicing disruptions, we carried out a detailed analysis of AR gene structure in the LuCaP 86.2 and CWR-R1 models of CRPCa. By deletion-spanning PCR, we discovered a 8579-bp deletion of AR exons 5, 6 and 7 in the LuCaP 86.2 xenograft, which provides a rational explanation for synthesis of the truncated AR v567es AR variant in this model. Similarly, targeted resequencing of the AR gene in CWR-R1 cells led to the discovery of a 48-kb deletion in AR intron 1. This intragenic deletion marked a specific CWR-R1 cell population with enhanced expression of the truncated AR-V7/AR3 variant, a high level of androgen-independent AR transcriptional activity and rapid androgen independent growth. Together, these data demonstrate that structural alterations in the AR gene are linked to stable gain-of-function splicing alterations in CRPCa.

摘要

雄激素受体 (AR) 在去势抵抗性前列腺癌 (CRPCa) 中的再激活是去势治疗 (ADT) 耐药的基础。AR 基因的选择性剪接和合成缺乏 AR 配体结合域的组成性激活的羧基末端截断 AR 变体已成为 CRPCa 中 ADT 耐药的重要机制。在之前的研究中,我们证明了 CRPCa 22Rv1 细胞中 AR 剪接的改变与 AR 外显子 3 和侧翼序列的 35kb 内含子串联重复有关。在这项研究中,我们证明了 PCa 细胞系、异种移植和临床标本中存在复杂的 AR 基因拷贝数失衡模式。为了研究这些拷贝数失衡是否反映了可能与剪接中断相关的 AR 基因重排,我们对 CRPCa 的 LuCaP 86.2 和 CWR-R1 模型中的 AR 基因结构进行了详细分析。通过缺失跨越 PCR,我们在 LuCaP 86.2 异种移植中发现了 AR 外显子 5、6 和 7 的 8579bp 缺失,这为该模型中截断的 AR v567es AR 变体的合成提供了合理的解释。同样,对 CWR-R1 细胞中 AR 基因的靶向重测序导致发现了 AR 内含子 1 中的 48kb 缺失。这种基因内缺失标志着 CWR-R1 细胞群体中 AR-V7/AR3 变体的表达增强,以及无雄激素的 AR 转录活性和快速无雄激素生长。总之,这些数据表明,AR 基因的结构改变与 CRPCa 中稳定的功能获得性剪接改变有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/2d5ccd759d1f/nihms-343813-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/16e30146ffdb/nihms-343813-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/542219921d09/nihms-343813-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/311e80216c0a/nihms-343813-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/b275fd02b8ad/nihms-343813-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/10e36f3da5b0/nihms-343813-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/785b375d5720/nihms-343813-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/2d5ccd759d1f/nihms-343813-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/16e30146ffdb/nihms-343813-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/542219921d09/nihms-343813-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/311e80216c0a/nihms-343813-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/b275fd02b8ad/nihms-343813-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/10e36f3da5b0/nihms-343813-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/785b375d5720/nihms-343813-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59c7/3337879/2d5ccd759d1f/nihms-343813-f0007.jpg

相似文献

1
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.雄激素受体基因内缺失与前列腺癌进展模型中的雄激素受体剪接变体表达和活性相关。
Oncogene. 2012 Nov 8;31(45):4759-67. doi: 10.1038/onc.2011.637. Epub 2012 Jan 23.
2
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.雄激素受体在前列腺癌进展的细胞模型中的基因内重排和改变的 RNA 剪接。
Cancer Res. 2011 Mar 15;71(6):2108-17. doi: 10.1158/0008-5472.CAN-10-1998. Epub 2011 Jan 19.
3
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.在去势抵抗性前列腺癌中表达的组成性激活的雄激素受体剪接变体需要全长雄激素受体。
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.
4
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.一种新型雄激素受体外显子的剪接产生一种组成型活性雄激素受体,介导前列腺癌治疗耐药性。
Cancer Res. 2008 Jul 1;68(13):5469-77. doi: 10.1158/0008-5472.CAN-08-0594.
5
Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.雄激素受体及其剪接变体AR-V7在LNCaP前列腺癌细胞中对FOXA1敏感基因有不同的调控作用。
Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.
6
The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7.RNA结合蛋白Sam68调节雄激素受体剪接变体AR-V7的表达和转录功能。
Sci Rep. 2015 Aug 27;5:13426. doi: 10.1038/srep13426.
7
Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.Vav3增强雄激素受体剪接变体活性,对去势抵抗性前列腺癌的生长和存活至关重要。
Mol Endocrinol. 2012 Dec;26(12):1967-79. doi: 10.1210/me.2012-1165. Epub 2012 Sep 28.
8
Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line.鉴定新型截短雄激素受体 (AR) 突变体,包括 22Rv1 激素难治性前列腺癌 (PCa) 细胞系中未报道的前体 mRNA 剪接变异体。
Hum Mutat. 2010 Jan;31(1):74-80. doi: 10.1002/humu.21138.
9
Mechanisms of the androgen receptor splicing in prostate cancer cells.雄激素受体剪接在前列腺癌细胞中的机制。
Oncogene. 2014 Jun 12;33(24):3140-50. doi: 10.1038/onc.2013.284. Epub 2013 Jul 15.
10
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.雄激素剥夺在前列腺癌中快速诱导雄激素受体剪接变体
Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

引用本文的文献

1
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.SOX2利用FOXA1作为异源转录伙伴来驱动去势抵抗性前列腺癌的增殖。
bioRxiv. 2025 Jul 19:2025.07.18.664790. doi: 10.1101/2025.07.18.664790.
2
Molecular Mechanisms of Castration-Resistant Prostate Cancer Progression.去势抵抗性前列腺癌进展的分子机制
Cureus. 2025 May 9;17(5):e83813. doi: 10.7759/cureus.83813. eCollection 2025 May.
3
Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells.

本文引用的文献

1
Abiraterone and increased survival in metastatic prostate cancer.阿比特龙与转移性前列腺癌患者的生存获益
N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.
2
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.雄激素受体剪接变体在前列腺癌骨转移中的表达与去势抵抗和生存期短有关。
PLoS One. 2011 Apr 28;6(4):e19059. doi: 10.1371/journal.pone.0019059.
3
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
雄激素非依赖性前列腺癌细胞中AR和AR-V7的共价去稳定降解剂
bioRxiv. 2025 Feb 16:2025.02.12.637117. doi: 10.1101/2025.02.12.637117.
4
The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells.同源框转录因子NKX3.1在去势抵抗性前列腺癌细胞中发挥致癌作用。
Cancers (Basel). 2025 Jan 18;17(2):306. doi: 10.3390/cancers17020306.
5
Systems-level liquid biopsy in advanced prostate cancer.晚期前列腺癌的系统水平液体活检
Endocr Relat Cancer. 2025 Jan 17;32(3). doi: 10.1530/ERC-24-0274. Print 2025 Mar 1.
6
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.雄激素受体改变为转移性去势抵抗性前列腺癌患者循环肿瘤DNA检测提供信息。
Nat Commun. 2024 Dec 11;15(1):10648. doi: 10.1038/s41467-024-54847-1.
7
Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics.雄激素受体结构和功能的研究进展及新一代 AR 靶向治疗药物的研发进展。
Steroids. 2024 Oct;210:109486. doi: 10.1016/j.steroids.2024.109486. Epub 2024 Aug 5.
8
Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation.临床相关的转移性前列腺癌人源化小鼠模型有助于治疗评估。
Mol Cancer Res. 2024 Sep 4;22(9):826-839. doi: 10.1158/1541-7786.MCR-23-0904.
9
Androgen receptor and estrogen receptor variants in prostate and breast cancers.前列腺癌和乳腺癌中的雄激素受体与雌激素受体变体
J Steroid Biochem Mol Biol. 2024 Jul;241:106522. doi: 10.1016/j.jsbmb.2024.106522. Epub 2024 Apr 17.
10
Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use.dmrFABP5对前列腺癌单独或与现有药物联合使用的实验性治疗效果。
Am J Cancer Res. 2024 Jan 15;14(1):300-323. doi: 10.62347/YPPT5752. eCollection 2024.
转移性前列腺癌的新策略:靶向雄激素受体信号通路。
Clin Cancer Res. 2011 Apr 1;17(7):1649-57. doi: 10.1158/1078-0432.CCR-10-0567. Epub 2011 Mar 3.
4
The genomic complexity of primary human prostate cancer.原发性人类前列腺癌的基因组复杂性。
Nature. 2011 Feb 10;470(7333):214-20. doi: 10.1038/nature09744.
5
Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.在前列腺癌中,通过将雄烷二醇瘤内生物转化为二氢睾酮来激活雄激素受体。
Cancer Res. 2011 Feb 15;71(4):1486-96. doi: 10.1158/0008-5472.CAN-10-1343. Epub 2011 Feb 8.
6
Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.雄激素受体在前列腺癌进展的细胞模型中的基因内重排和改变的 RNA 剪接。
Cancer Res. 2011 Mar 15;71(6):2108-17. doi: 10.1158/0008-5472.CAN-10-1998. Epub 2011 Jan 19.
7
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors.拷贝数和靶向突变分析揭示转移性前列腺肿瘤中的新型体细胞事件。
Genome Res. 2011 Jan;21(1):47-55. doi: 10.1101/gr.107961.110. Epub 2010 Dec 8.
8
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.在去势抵抗性前列腺癌中表达的组成性激活的雄激素受体剪接变体需要全长雄激素受体。
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.
9
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.在人类前列腺癌中,雄激素受体剪接变体的频繁发生导致去势抵抗。
J Clin Invest. 2010 Aug;120(8):2715-30. doi: 10.1172/JCI41824. Epub 2010 Jul 19.
10
Genome-wide mapping and assembly of structural variant breakpoints in the mouse genome.在小鼠基因组中进行全基因组范围内结构变异断点的图谱绘制和组装。
Genome Res. 2010 May;20(5):623-35. doi: 10.1101/gr.102970.109. Epub 2010 Mar 22.